Cydan, an orphan-drug accelerator bankrolled by New Enterprise Associates and Pfizer Ventures, has secured another $10 million in venture cash.
Edimer aims to use the new funds to bankroll a midstage study of its lead candidate EDI200, a recombinant protein intended to restore normal development in newborns with XLHED.
New Enterprise Associates (NEA) has dipped into its ample coffers to provide Cartiva with $4.3 million. The capital infusion backs the startup's ongoing clinical trial of a cartilage replacement implant in patients with osteoarthritis.
David Mott at New Enterprise Associates has put together a $20 million round to back 3-V Biosciences, an upstart biotech with deep roots in Switzerland's scientific community and an office in Silicon Valley.
After a period of revamping a venture strategy gone wrong, Atlas Venture has come out today with news about an oversubscribed 9 th fund of $265 million. It's a rare comeback story in a VC industry that is suffering from an overall lack of capital to fuel startups in biotech and other high-risk-and-reward sectors.
Topera first disclosed its $25 million Series C financing in a regulatory filing in March, but now it's revealing the investors behind the deal, and the lead one is a big fish indeed--New Enterprise Associates.
Ask any biotech exec in the business of drug and device development about the funding environment these days, and you'll most likely hear the word "tough" inside of three seconds. The...
David Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer Ventures.
David Mott at New Enterprise Associates has spearheaded the development of an orphan drug accelerator that plans to hunt down the best in vivo-stage assets in academia, biopharma and the nonprofits, assemble them in a portfolio of rare disease therapies and mold them into pipeline programs that can be spun out into a slate of new biotech companies.
Closing in on the selection of its lead cancer program, San Francisco-based Cleave Biosciences has welcomed the deep-pocketed player New Enterprise Associates to its list of venture backers and topped up its Series A with a $10 million investment in its early-stage drug research work.